Epidemiology and persistence of rhinovirus in pediatric lung transplantation.
community-acquired respiratory virus (CARV)
forced expiratory volume (FEV1)
human rhinovirus (HRV)
lung transplantation
pediatrics
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
02
2020
revised:
19
06
2020
accepted:
12
07
2020
pubmed:
21
7
2020
medline:
12
8
2021
entrez:
21
7
2020
Statut:
ppublish
Résumé
Infection with rhinovirus (HRV) occurs following pediatric lung transplantation. Prospective studies documenting frequencies, persistence, and progression of HRV in this at-risk population are lacking. In the Clinical Trials in Organ Transplant in Children prospective observational study, we followed 61 lung transplant recipients for 2 years. We quantified molecular subtypes of HRV in serially collected nasopharyngeal (NP) and bronchoalveolar lavage (BAL) samples and correlated them with clinical characteristics. We identified 135 community-acquired respiratory infections (CARV) from 397 BAL and 480 NP samples. We detected 93 HRV events in 42 (68.8%) patients, 22 of which (23.4%) were symptomatic. HRV events were contiguous with different genotypes identified in 23 cases, but symptoms were not preferentially associated with any particular species. Nine (9.7%) HRV events persisted over multiple successive samples for a median of 36 days (range 18-408 days). Three persistent HRV were symptomatic. When we serially measured forced expiratory volume in one second (FEV1) in 23 subjects with events, we did not observe significant decreases in lung function over 12 months post-HRV. In conjunction with our previous reports, our prospectively collected data indicate that molecularly heterogeneous HRV infections occur commonly following pediatric lung transplantation, but these infections do not negatively impact clinical outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Infection with rhinovirus (HRV) occurs following pediatric lung transplantation. Prospective studies documenting frequencies, persistence, and progression of HRV in this at-risk population are lacking.
METHODS
METHODS
In the Clinical Trials in Organ Transplant in Children prospective observational study, we followed 61 lung transplant recipients for 2 years. We quantified molecular subtypes of HRV in serially collected nasopharyngeal (NP) and bronchoalveolar lavage (BAL) samples and correlated them with clinical characteristics.
RESULTS
RESULTS
We identified 135 community-acquired respiratory infections (CARV) from 397 BAL and 480 NP samples. We detected 93 HRV events in 42 (68.8%) patients, 22 of which (23.4%) were symptomatic. HRV events were contiguous with different genotypes identified in 23 cases, but symptoms were not preferentially associated with any particular species. Nine (9.7%) HRV events persisted over multiple successive samples for a median of 36 days (range 18-408 days). Three persistent HRV were symptomatic. When we serially measured forced expiratory volume in one second (FEV1) in 23 subjects with events, we did not observe significant decreases in lung function over 12 months post-HRV.
CONCLUSION
CONCLUSIONS
In conjunction with our previous reports, our prospectively collected data indicate that molecularly heterogeneous HRV infections occur commonly following pediatric lung transplantation, but these infections do not negatively impact clinical outcomes.
Identifiants
pubmed: 32686323
doi: 10.1111/tid.13422
pmc: PMC7900771
mid: NIHMS1627018
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13422Subventions
Organisme : NIAID NIH HHS
ID : U01 AI077810
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
pubmed: 18096473
Epidemiol Infect. 1993 Feb;110(1):145-60
pubmed: 8432318
Am J Respir Crit Care Med. 2012 Nov 1;186(9):886-91
pubmed: 22923659
J Infect Dis. 2017 Nov 27;216(9):1104-1111
pubmed: 28968668
Pediatr Infect Dis J. 2010 Aug;29(8):717-20
pubmed: 20305581
Am J Rhinol. 1998 Jan-Feb;12(1):17-20
pubmed: 9513654
J Med Virol. 2006 May;78(5):644-50
pubmed: 16555289
J Heart Lung Transplant. 2002 May;21(5):559-66
pubmed: 11983546
Clin Infect Dis. 2019 Sep 13;69(7):1192-1197
pubmed: 30561555
Clin Transplant. 2013 Jan-Feb;27(1):E64-71
pubmed: 23278569
Thorax. 2014 Jan;69(1):32-8
pubmed: 24025442
J Med Virol. 2009 Aug;81(8):1498-507
pubmed: 19551831
Breathe (Sheff). 2017 Sep;13(3):e56-e64
pubmed: 28955406
Am J Respir Crit Care Med. 2006 Dec 15;174(12):1392-9
pubmed: 17008640
Pediatr Transplant. 2010 May;14(3):431-6
pubmed: 20214745
PLoS One. 2007 Oct 03;2(10):e966
pubmed: 17912345
Microbes Infect. 2012 Jun;14(6):485-94
pubmed: 22285901
Am J Transplant. 2017 May;17(5):1304-1312
pubmed: 27615811
Am J Respir Crit Care Med. 2008 Oct 15;178(8):876-81
pubmed: 18658110
J Clin Virol. 2015 Mar;64:1-5
pubmed: 25728070
Clin Infect Dis. 2010 Jul 15;51(2):163-70
pubmed: 20524853
PLoS One. 2011;6(6):e21163
pubmed: 21713005
Am J Transplant. 2019 Dec;19(12):3284-3298
pubmed: 31216376
J Thorac Dis. 2017 Aug;9(8):2684-2691
pubmed: 28932576
Transplantation. 2010 Apr 27;89(8):1028-33
pubmed: 20075787
Transpl Infect Dis. 2009 Aug;11(4):304-12
pubmed: 19422670
Transplant Direct. 2018 Jul 11;4(8):e370
pubmed: 30255130
Am J Transplant. 2011 May;11(5):1071-8
pubmed: 21521473
Eur Respir J. 2006 Jul;28(1):131-7
pubmed: 16510454
Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7
pubmed: 15130908
Am J Transplant. 2005 Aug;5(8):2031-6
pubmed: 15996256